ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

ClinicalTrials.gov ID: NCT04551066

Public ClinicalTrials.gov record NCT04551066. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 12:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Study identification

NCT ID
NCT04551066
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Incyte Corporation
Industry
Enrollment
252 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 23, 2021
Primary completion
Aug 2, 2023
Completion
Nov 24, 2024
Last update posted
Oct 20, 2025

2021 – 2024

United States locations

U.S. sites
36
U.S. states
20
U.S. cities
32
Facility City State ZIP Site status
Alaska Oncology and Hematology Anchorage Alaska 99508
Mayo Clinic Rochester Phoenix Arizona 85054
Sutter Health Alta Bates Summit Medical Center Absmc Alta Bates Summit Comprehensive Cancer Center Berkeley California 94704
CCARE Fresno California 93720
California Research Institute (Cri) Los Angeles California 90027-6005
UCLA School of Medicine Los Angeles California 90095-3075
Scripps Clinic San Diego California 92103
Coastal Integrated Cancer Care-Cicc San Luis Obispo California 93401
Stamford Hospital-Medical Oncology Hematology Stamford Connecticut 06904
Georgetown University Washington D.C. District of Columbia 20057
Emory University Atlanta Georgia 30322
University of Kansas Hospital Authority Westwood Kansas 66205
University of Kentucky-Markey Cancer Center Lexington Kentucky 40536
Tulane University New Orleans Louisiana 70112
Johns Hopkins University Baltimore Maryland 21287
Massachusetts General Hospital Boston Massachusetts 02114
Midamerica Cancer Care Kansas City Missouri 64114
New Jersey Hematology Oncology Associates Llc Brick New Jersey 08724
Morristown Medical Center-Atlantic Health System Morristown New Jersey 07960
Roswell Park Cancer Institute Buffalo New York 14263
Westchester Medical Center Advanced Oncology and Infusion Center Hawthorne New York 10532
Mount Sinai School of Medicine New York New York 10029
Memorial Sloan Kettering Cancer Center New York New York 10065
Montefiore Medical Center The Bronx New York 10467
Duke Cancer Center Durham North Carolina 27710
Wake Forest Baptist Medical Center Winston-Salem North Carolina 27157
Ohio State University Columbus Ohio 43210
Kaiser Permanente-Northwest Portland Oregon 97227
Oregon Health & Science University Portland Oregon 97239
Avera Cancer Institute Sioux Falls South Dakota 57103
Texas Oncology-Baylor Sammons Cancer Center Dallas Texas 75246-2092
Kelsey Seybold Clinic Houston Texas 77025
Houston Methodist Hospital Houston Texas 77030
Renovatio Clinical Spring Texas 77380
Providence Regional Medical Center Everett Everett Washington 98201
Seattle Cancer Care Alliance Seattle Washington 98109

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 141 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04551066, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 20, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04551066 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →